All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F22%3A00079078" target="_blank" >RIV/00209805:_____/22:00079078 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/22:00128009

  • Result on the web

    <a href="https://sciendo.com/pdf/10.2478/afpuc-2022-0006" target="_blank" >https://sciendo.com/pdf/10.2478/afpuc-2022-0006</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.2478/afpuc-2022-0006" target="_blank" >10.2478/afpuc-2022-0006</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

  • Original language description

    Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8 %). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database

  • CEP classification

  • OECD FORD branch

    30104 - Pharmacology and pharmacy

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2022

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    European Pharmaceutical Journal

  • ISSN

    2453-6725

  • e-ISSN

    2453-6725

  • Volume of the periodical

    69

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    PL - POLAND

  • Number of pages

    3

  • Pages from-to

    84-86

  • UT code for WoS article

  • EID of the result in the Scopus database

    2-s2.0-85136909996